Morgan Stanley raised the firm’s price target on Alnylam (ALNY) to $405 from $312 and keeps an Equal Weight rating on the shares. Amvuttra sales meaningfully beat the high end of buyside expectations and the firm expects launch momentum to continue, though it maintains an Equal Weight rating as the analyst sees opportunity for greater upside elsewhere in the firm’s biotech coverage.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Cautious Optimism: Alnylam Pharma’s Strong TTR Franchise Growth and Hold Rating
- Alnylam price target raised to $460 from $329 at Barclays
- Alnylam Pharmaceuticals Reports Strong Q2 2025 Growth
- Alnylam Pharma’s Strong Financial Performance and Strategic Partnerships Justify Buy Rating
- Alnylam Pharma’s Strong Q2 2025 Performance and Raised Guidance Justify Buy Rating and Increased Price Target